+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid



External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid



Hepatology Communications 2(6): 676-682



The United Kingdom-Primary Biliary Cholangitis (UK-PBC) risk scores are a set of prognostic models that estimate the risk of end-stage liver disease in patients with PBC at 5-, 10- and 15-year intervals. They have not been externally validated outside the United Kingdom. In this retrospective, external validation study, data were abstracted from outpatient charts and discrimination and calibration of the UK-PBC risk scores were assessed. A total of 464 patients with PBC treated with ursodeoxycholic acid were included. The median diagnosis age was 52.4 years, and 88% were female patients. The cumulative incidence of events was 6%, 9%, and 15% at 5, 10, and 15 years, respectively. Concordance (c-statistic) was 0.88, 0.85, and 0.84 using the 5-, 10- and 15-year risk scores, respectively, which was slightly lower than values observed in the United Kingdom validation cohort. Using the 5-year risk score, more events were observed than predicted (25 versus 16.8; P = 0.046); using the 10-year risk score, there was no difference between the observed and predicted number of events (35 versus 44.9; P = 0.14); conversely, using the 15-year risk score, fewer events were observed than predicted (46 versus 67.5; P = 0.009). Limiting evaluation by the 15-year UK-PBC risk score to those with >10 years of follow-up demonstrated no difference between observed and predicted events. Using the 5-year risk score, patients within the highest quartile had statistically significant worse event-free survival compared to the rest of the cohort: 82% versus 98% at 5 years, 73% versus 97% at 10 years, and 58% versus 93% at 15 years. Conclusion: In patients assessed at a North American tertiary medical center, the UK-PBC risk score had excellent discrimination and was reasonably calibrated both in the short and long term. (Hepatology Communications 2018;2:676-682).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064363575

Download citation: RISBibTeXText

PMID: 29881819

DOI: 10.1002/hep4.1186


Related references

Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Hepatology Communications 2(6): 683-692, 2018

Analysis of predictive response scores to treatment with ursodeoxycholic acid in patients with primary biliary cholangitis. Medicina Clinica 152(10): 377-383, 2019

Bezafibrate for primary biliary cholangitis : Bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis (BEZURSO) trial. Der Internist 59(12): 1344-1346, 2018

Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. Clinical Gastroenterology and Hepatology 17(7): 1379-1387.E3, 2019

Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. Journal of Gastroenterology and Hepatology 34(7): 1236-1241, 2019

A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. Hepatology Communications 2(5): 484-491, 2018

Urinary excretion of ursodeoxycholic acid during treatment of patients with primary biliary cirrhosis and primary sclerosing cholangitis. Journal of Hepatology 7, 1988

Ursodeoxycholic acid therapy plays an immunomodulatory and anti-apoptotic role in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Journal of Hepatology 38(Suppl. 2): 208, 2003

Ursodeoxycholic acid therapy affects the cytokine network and plays an immunomodulatory role in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 36(4 Part 2): 499A, 2002

Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis. Zhonghua Gan Zang Bing Za Zhi 27(1): 73-76, 2019

Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. Hepatology Research 48(9): 727-734, 2018

Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. Journal of Gastrointestinal and Liver Diseases 27(3): 273-279, 2018

Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid. Current Gastroenterology Reports 1(1): 38-41, 2000

What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?. Digestive Diseases 35(4): 359-366, 2017

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis and primary sclerosing cholangitis in pregnancy. Hepatology 36(4 Part 2): 491A, 2002